Aprocitentan

Unassigned

New Medicines

Resistant hypertension

Information

New molecular entity
Janssen
Janssen

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Dual endothelin receptor antagonist, the major active metabolite of macitentan
Over a quarter of adults in the UK have hypertension. Prevalence is rising as the population ages. Overall, the prevalence of hypertension (at least ≥140/90 mm Hg or on treatment for hypertension) in those aged over 35 years in the 2010 health survey for England was 31% in men and 28% in women [1]. Prevalence of RHT has been thoroughly studied in the recent years, ranging from about 5 to 30% [2].
Resistant hypertension
Oral